OVID — Ovid Therapeutics Share News
0.000.00%
Last trade - 00:00- $462.86m
- $345.64m
- $7.25m
Brief: Ovid Therapeutics Enters Agreement With Immedica Pharma AB For Sale Of Future Ganaxolone Royalties
Ovid Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Ovid Therapeutics Q1 Operating Expenses USD 12.68 Million
Ovid Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Ovid Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Ovid Therapeutics Q4 EPS USD -0.13
Ovid Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Ovid Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos To Board Of Directors
Brief: Ovid Therapeutics Inc - Receives Nasdaq Notice For Minimum Bid Price Non-Compliance
Analysis: RFK Jr vow to purge FDA sets up collision with Big Pharma
Ovid Therapeutics Inc reports results for the quarter - Earnings Summary
Brief: Ovid Therapeutics Q3 EPS USD -0.2 Vs. IBES Estimate USD -0.2
Ovid Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating Ov329 Does Not Accumulate In Animal Eyes In Contrast With Vigabatrin
Ovid Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Ovid Therapeutics Q2 EPS USD 0.12 Vs. IBES Estimate USD -0.22
Ovid Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Ovid Therapeutics Expands Scientific Advisory Board